When it comes to breakthroughs, impatience is a virtue.

Highlights

Discovery of biomarkers to predict flares related to stress.

Knowing which ulcerative colitis patients will experience a flare due to stress can help them be prepared.

A new oral drug candidate that reduces inflammation:

Clinical trials are on the horizon to evaluate a drug that helps decrease a leaky gut barrier that allows bacteria and toxins through.

The Crohn’s & Colitis Foundation has played a role in every major research breakthrough in IBD.

More than $500 million in research and 2,500 research projects to date.

New high-tech capsule delivers targeted treatment directly to the colon.

IBD Plexus*: Accelerating research
Our revolutionary research platform, IBD Plexus*, continues to grow. 200 research projects worldwide now use data we’ve collected—including 38,000 biosamples—to accelerate and shave years off advancing new products to market.

Monitoring IBD in Real Time: Wearable device to measure biomarkers in sweat.

A new non-invasive monitor is being evaluated that lets patients get real-time information about their inflammatory status without waiting for invasive testing.

Patients help us determine our research priorities for the next five years.

2024 2025 2026 2027 2028

Challenges in IBD Research 2024, our new five-year roadmap that helps set our research priorities for the entire IBD research community, was developed in partnership with IBD scientists, patients, and caregivers.
We put patients first.
So it’s no wonder 85% of people with IBD who engage with us say we’ve played a positive role in their lives. IBD patients trust us as their source for education, guidance, and support every step of the way.

Helping patients and caregivers understand IBD.
4,000+ patients and caregivers stay up to date on the latest IBD information through “MyIBD Learning” educational programs that are both online and in-person.

Our IBD Help Center responded to 12,000 inquiries, offering help to patients in 170 languages worldwide.

Breaking down barriers to care among Black/African American IBD patients.
Black/African American IBD patients have higher rates of hospitalization and surgery. Through a new CDC grant, we’ve begun a five-year partnership with the University of Alabama to help identify barriers, raise awareness, and improve care for these patients.

We fight to protect your access to care.
We’ve led efforts to pass Step Therapy laws in 37 states, allowing decisions about medication to remain between clinicians and patients.

We led a rally alongside IBD healthcare professionals and patients to help deter one of the nation’s largest insurers from implementing a policy that would require prior authorization, delaying vital procedures for IBD patients.